<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   Form 10-KSB/A



[X]  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934

              For the fiscal year ended        December 31, 2001
                                          ---------------------------------

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     For the transition period from _______________________ to _____________

                        Commission file number 000-27339
                            ------------------------

                                 BEPARIKO BIOCOM
                   ------------------------------------------
                 (Name of small business issuer in its charter)


         NEVADA                                        88-0426887
-------------------------                  -----------------------------------
(State or other jurisdiction              (I.R.S. Employer Identification No.)
of incorporation or organization)


      One Belmont Avenue, Suite 417
        Bala Cynwyd, Pennsylvania                             19004
----------------------------------------               -----------------------
(Address of principal executive offices)                     (Zip Code)

Issuer's telephone number:     (610) 660-5906
                           -------------------------------

Securities registered under Section 12(b) of the Exchange Act:

       Title of each class            Name of each exchange on which registered

              None                                 Not Applicable
-----------------------------------   -----------------------------------------

Securities registered under Section 12(g) of the Exchange Act:

                     Common Stock $0.001 par value per share
-------------------------------------------------------------------------------
                                (Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. [X] Yes [ ] No

<PAGE>


Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]

State issuer's revenues for its most recent fiscal year:       $0.00
                                                               -----

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates based on the last sale price for the Registrant's common
stock: As at April 3 2002 the aggregate market value of the Company's Common
Stock (based upon the last reported sale price on the National Association of
Securities Dealers OTC Bulletin Board), excluding outstanding shares
beneficially owned by affiliates, was approximately $8,337,500.00, being $1.45
per share.

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date. As at April 10 2002, there were
5,750,000 shares of Common stock issued and outstanding.

                       DOCUMENTS INCORPORATED BY REFERENCE

None

Transitional Small Business Disclosure Format (Check one): Yes     ; No   X
                                                              -----     -----

                                     -ii-

<PAGE>




                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this Report to be signed on its behalf by the undersigned, thereunto duly
authorized.


          BEPARIKO BIOCOM
-----------------------------------------------------------------------
          (Registrant)


By:      /s/ "Cecile T. Coady"
         --------------------------------------------------------------
          Cecile T. Coady
          President and Director

Date:    June 7, 2002

In accordance with the Exchange Act, this Report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.

By:      /s/ "Cecile T. Coady"
         --------------------------------------------------------------
         Cecile T. Coady
         President and Director (Principal executive, financial and
         accounting officer)

Date:    June 7, 2002


                                      -21-
<PAGE>

                          INDEPENDENT AUDITOR'S REPORT

Board of Directors
Bepariko Biocom
Las Vegas, Nevada

         I have audited the accompanying balance sheets of Bepariko Biocom (a
development stage company), as of December 31, 2001 and December 31, 2000 and
the related statements of stockholders' equity for December 31, 2001 and
December 31, 2000 and statements of operations and cash flows for the two years
ended December 31, 2001 and December 31, 2000 and the period of April 2, 1997
(inception) to December 31, 2001. These financial statements are the
responsibility of the Company's management. My responsibility is to express an
opinion on these financial statements based on my audit.

         I conducted my audit in accordance with generally accepted auditing
standards. Those standards require that I plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
I believe that my audit provides a reasonable basis for my opinion.

         In my opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of Bepariko Biocom as
of December 31, 2001 and December 31, 2000 and the related statements of
stockholders' equity for December 31, 2001 and December 31, 2000 and statements
of operations and cash flows for the two years ended December 31, 2001 and
December 31, 2000 and the period April 2, 1997 (inception) to December 31, 2001
in conformity with generally accepted accounting principles.

         The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. As discussed in Note 5 to the
financial statements, the Company has had no operations and has no established
source of revenue. This raises substantial doubt about its ability to continue
as a going concern. Management's plan in regard to these matters are also
described in Note 5. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.



Kurt D. Salinger C.P.A.
February 12, 2002



                                     -F-1-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                                 BALANCE SHEETS

                                     ASSETS


<TABLE>
<CAPTION>
                                                                 December 31, 2001     December 31, 2000

<S>                                                                  <C>                   <C>
CURRENT ASSETS
         Cash                                                        $      47             $       0
         Accounts Receivable                                         $ 250,000             $       0
                                                                     ---------             ---------

         TOTAL CURRENT ASSETS                                        $ 250,047             $       0
                                                                     ---------             ---------

                  TOTAL ASSETS                                       $ 250,047             $       0
                                                                     =========             =========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
         Accounts Payable                                            $ 178,652             $   3,100
         Notes Payable                                               $ 318,000             $       0
                                                                     ---------             ---------

         TOTAL CURRENT LIABILITIES                                   $ 496,652             $   3,100



STOCKHOLDERS' EQUITY
         Preferred Stock, $.001 par value authorized
         10,000,000 shares; issued and outstanding at
         Dec. 31, 2001  none                                         $       0             $       0

         Common Stock, $.001 par value authorized 100,000,000
         shares; issued and outstanding at
         Dec. 31, 2000 5,750,000 shares                                                    $   5,750
         Dec. 31, 2001 5,750,000 shares                              $   5,750

         Additional Paid In Capital                                  $ 342,324             $  32,324

         Deficit Accumulated During Development Stage                ($594,679)            ($ 41,174)
                                                                     ---------             ---------

         TOTAL STOCKHOLDERS' EQUITY                                  ($246,605)            ($  3,100)
                                                                     ---------             ---------

                  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY         $ 250,047             $       0
                                                                     =========             =========
</TABLE>


         See accompanying notes to financial statements.


                                     -F-2-
<PAGE>

                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS


<TABLE>
<CAPTION>
                                                                                     April 2, 1997
                                         Year Ended            Year Ended           (inception) to
                                       Dec. 31, 2001          Dec. 31, 2000          Dec. 31, 2001

<S>                                    <C>                   <C>                    <C>
INCOME
Revenue                                $         0             $         0             $         0
                                       -----------             -----------             -----------

TOTAL INCOME                           $         0             $         0             $         0

EXPENSES

General, Selling
and Administrative                     $   225,770             $    21,600             $   266,794

Amortization                           $         0             $         0             $       150

Interest expense                       $   327,735             $         0             $   327,735
                                       -----------             -----------             -----------

TOTAL EXPENSES                         $   553,505             $    21,600             $   594,679
                                       -----------             -----------             -----------

NET PROFIT (LOSS)                      ($  553,505)            ($   21,600)            ($  594,679)
                                       ===========             ===========             ===========

NET PROFIT (LOSS)
PER SHARE                              ($   0.0963)            ($   0.0038)            ($   0.1034)
                                       ===========             ===========             ===========


AVERAGE NUMBER OF SHARES
OF COMMON STOCK OUTSTANDING              5,750,000               5,750,000               5,750,000
                                       ===========             ===========             ===========
</TABLE>


         See accompanying notes to financial statements.


                                     -F-3-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
                                December 31, 2001


<TABLE>
<CAPTION>
                                                   Common Stock
                                                   ------------                                        (Deficit)
                                            Number                              Additional            Accumulated
                                              of                                 Paid In                 During
                                            Shares              Amount           Capital           Development Stage
                                            ------              ------           -------           -----------------
<S>                                     <C>                    <C>             <C>                  <C>
Balance,
December 31, 1998                           750,000                $750            $17,324              ($17,976)

Net Loss,
December 31, 1999                                                                                        ($1,598)
                                         ----------          ----------         ----------            ----------

Balance, Dec. 31, 1999                      750,000                $750            $17,324              ($19,574)

Issued for cash
January 21, 2000                          5,000,000              $5,000            $15,000                    $0


Net Loss,
December 31, 2000                                                                                       ($21,600)
                                         ----------          ----------         ----------            ----------

Balance,
December 31, 2000                         5,750,000              $5,750            $32,324              ($41,174)

Beneficial conversion discount                                                    $310,000

Net Loss,
December 31, 2001                                                                                      ($553,505)
                                         ----------          ----------         ----------            ----------

Balance,
December 31, 2001                         5,750,000              $5,750           $342,324              ($594,679)
                                         ==========          ==========         ==========            ===========
</TABLE>


         See accompanying notes to financial statements.


                                     -F-4-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS


<TABLE>
<CAPTION>
                                                                                                        April 2, 1997
                                                           Year Ended Dec.        Year Ended Dec.      (inception) to
                                                              31, 2001               31, 2000           Dec. 31, 2001

<S>                                                        <C>                 <C>                  <C>
CASH FLOWS FROM OPERATING ACTIVITIES

Net (Loss)                                                       ($553,505)            ($21,600)            ($594,679)

Adjustment to reconcile net loss to net cash provided
by operating activities

Accounts Receivable                                                      $0                  $0                    $0

Accounts Payable                                                   $175,552                  $0              $171,352

Amortization                                                             $0                  $0                  $150
Officer Advances                                                         $0              $1,600                $7,300
Organization Costs                                                                                              ($150)
Amortization of Discounts                                          $310,000                                  $310,000
                                                                 ----------         -----------           -----------

Net cash used in operating activities                              ($67,953)            ($20,000)           ($106,027)
                                                                 ----------         ------------          -----------
CASH FLOWS FROM INVESTING ACTIVITIES
Advances                                                          ($250,000)                  $0            ($250,000)
                                                                 ----------         ------------          -----------
CASH FLOWS FROM
FINANCING ACTIVITIES
Issue Notes Payable                                                $318,000                   $0             $318,000
Issue Common Stock                                                       $0              $20,000              $38,074
                                                                 ----------         ------------          -----------
Net cash provided by financing activities                          $318,000              $20,000             $356,074
                                                                 ----------         ------------          -----------
Net increase (decrease) in cash                                         $47                   $0                  $47

Cash, Beginning of Period                                                $0                   $0                   $0
                                                                 ----------         ------------          -----------

Cash, End of Period                                                     $47                   $0                  $47
                                                                 ==========         ============          ===========
</TABLE>


         See accompanying notes to financial statements.


                                     -F-5-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 1 - ORGANIZATION AND ACCOUNTING POLICIES

         The Company was incorporated April 2, 1997 under the laws of the State
of Nevada. The Company was organized to engage in any lawful activity. The
Company currently has no operations and, in accordance with SFAS #7, is
considered a development stage company.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

         Accounting Method
                  The Company records income and expenses on the accrual method
         of accounting.

         Estimates
                  The preparation of financial statements in conformity with
                  generally accepted accounting principles requires management
                  to make estimates and assumptions that affect the reported
                  amounts of assets and liabilities and disclosure of contingent
                  assets and liabilities at the date of the financial statements
                  and the reported amounts of revenue and expenses during the
                  reporting period. Actual results could differ from those
                  estimates.

         Cash and equivalents
                  The Company maintains a cash balance in a non-interest bearing
                  bank that currently does not exceed federally insured limits.
                  For the purpose of the statements of cash flows, all highly
                  liquid investments with the maturity of three months or less
                  are considered to be cash equivalents. There are no cash
                  equivalents December 31, 2001 or as of December 31, 2000.

         Income Taxes
                  Income taxes are provided for using the liability method of
                  accounting in accordance with Statement of Financial
                  Accounting Standards No. 109 (SFAS #109) "Accounting for
                  Income Taxes". A deferred tax asset or liability is recorded
                  for all temporary differences between financial and tax
                  reporting. Deferred tax expense (benefit) results from the net
                  change during the year of deferred tax assets and liabilities.


                                     -F-6-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

         Reporting on Costs of Start-Up Activities
                  In April 1998, the American Institute of Certified Public
                  Accountants issued Statement of position 98-5 ("SOP 98-5"),
                  "Reporting the Costs of Start-up Activities" which provides
                  guidance on the financial reporting of start-up costs and
                  organizational costs. It requires costs of start-up activities
                  and organizational costs to be expensed as incurred. SOP 98-5
                  is effective for fiscal years beginning after December 15,
                  1998 with initial adoption reported as the cumulative effect
                  of a change in accounting principle.

         Loss Per Share
                  Net loss per share is provided in accordance with Statement of
                  Financial Accounting Standards No. 128 (SFAS #128) "Earnings
                  Per Share". Basic loss per share is computed by dividing
                  losses available to common stockholders by the weighted
                  average number of common shares outstanding during the period.
                  Diluted loss per share reflects per share amounts that would
                  have resulted if dilutive common stock equivalents had been
                  converted to common stock. As of December 31, 2001 the Company
                  had no dilutive common stock equivalents such as stock
                  options.

         Year End
                  The Company has selected December 31st as its fiscal year end.

         Year 2000 Disclosure
                  The year 2000 issue had no effect on the Company.

NOTE 3 - INCOME TAXES

                  There is no provision for income taxes for the year ended
                  December 31, 2001. The Company's total deferred tax asset as
                  of December 31, 2001 is as follows:

                      Net operating loss carry forward             $284,679
                      Valuation allowance                          $284,679
                      Net deferred tax asset                             $0

                  The federal net operating loss carry forward will expire in
2017 to 2019.


                                     -F-7-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 4 - STOCKHOLDERS' EQUITY

         Common Stock
                  The authorized common stock of the Company consists of
                  100,000,000 shares with a par value of $0.001 per share.

                  On July 24, 1997 the Company issued 750,000 shares of its
                  $0.001 par value common stock in consideration of $18,074 in
                  cash to its directors.

                  On January 21, 2000 the Company completed a public offering
                  that was registered with the State of Nevada pursuant to
                  N.R.S. 90.490 and was in compliance with federal registration
                  pursuant to the Form SB-2 filed with the Securities and
                  Exchange Commission being declared effective on December 22,
                  1999. Subsequently, the Company sold 5,000,000 shares of its
                  common stock at a share price of $0.004 per share for a total
                  of $20,000 cash.

         Preferred Stock
                  The authorized preferred stock of the Company consists of
                  10,000,000 shares with a par value of $0.001 per share.

NOTE 5 - GOING CONCERN

                  The Company's financial statements are prepared using general
                  accepted accounting principles applicable to a going concern
                  which contemplates the realization of assets and liquidation
                  of liabilities in the normal course of business. However, the
                  Company does not have significant cash or other material
                  assets, nor does it have an established source of revenues
                  sufficient to cover its operating costs and to allow it to
                  continue as a going concern. The Director and officer of the
                  Company and certain of the shareholders and noteholders of the
                  Company have committed to advance funds to the Company as
                  required for working capital needs.



                                     -F-8-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 6 - RELATED PARTY TRANSACTIONS

                  The Company neither owns nor leases any real or personal
                  property. An officer of the Company provides office services
                  without charge. Such costs are immaterial to the financial
                  statements and accordingly, have not been reflected therein.
                  The officers and directors of the Company are involved in
                  other business opportunities. If a specific business
                  opportunity becomes available, such persons may face a
                  conflict in selecting between the Company and their other
                  business interests. The Company has not formulated a policy
                  for the resolution of such conflicts.

NOTE 7 - WARRANTS AND OPTIONS

                  There are no warrants or options outstanding to acquire any
                  additional shares of common or preferred stock.

NOTE 8 - OFFICER ADVANCES

                  While the Company was seeking additional capital to advance
                  its business plan, an officer of the Company has advanced
                  funds on behalf of the Company to pay for any costs incurred
                  by it. These funds are interest free.


NOTE 9 - NOTES PAYABLE

In April 2001, the Company entered into financing arrangements for an aggregate
of $310,000 with unrelated parties (the "Lenders") and issued Series 1
Promissory Notes (the "Series 1 Promissory Notes") to evidence such borrowings.
The Series 1 Promissory Notes bear interest at a rate of 10% per annum
calculated annually. The Series 1 Promissory Notes are due and payable on or
before the date (the "Due Date") which is the earlier of (i) September 1, 2001,
and (ii) the date that the Company completes the acquisition of all the GGC
shares. In addition, the Company granted to the Lenders, warrants to purchase an
aggregate of 155,000 shares of the Company's Common Stock at an exercise price
of $2.50 per share. The Series 1 Promissory Notes carry a right of set-off,
which provides that the Lenders may set-off the principal amount of the Series 1
Promissory Notes against a subscription for shares of the Company's Common Stock
at an issue price of $2.50.

Under Emerging Issues Task Force ("EITF") 00-27: Application of Issue No. 98-5
to Certain Convertible Instruments the Company has allocated the proceeds from
issuance of the convertible Series 1 Promissory Notes and warrants based on a
fair value basis of each item. Consequently, the convertible Series 1 Promissory
Notes were recorded at a discount. An additional beneficial conversion discount
was recorded since the Series 1 Promissory Notes were convertible into common
shares of stock at a rate of $2.50 per share while the prevailing common stock
share price was $5.00. Under EITF 00-27 the note discounts amounting to $310,000
were amortized over the four month period from the date of issuance to the
stated redemption date of the notes which is September 1, 2001.


                                     -F-9-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 10 - CORRECTION OF AN ERROR

The original financial statements issued for these periods have been corrected
to conform them to generally accepted accounting principles.

The corrections involve applying Emerging Issues Task Force ("EITF") 00-27:
Application of Issue No. 98-5 to Certain Convertible Instruments and the Company
has now allocated the proceeds from issuance of the convertible Series 1
Promissory Notes and warrants based on a fair value basis of each item.
Consequently, the convertible Series 1 Promissory Notes have been recorded at a
discount. An additional beneficial conversion discount has been recorded since
the Series 1 Promissory Notes were convertible into common shares of stock at a
rate of $2.50 per share while the prevailing common stock share price was $5.00.
Under EITF 00-27 the note discounts amounting to $310,000 now have been
amortized over the four-month period from the date of issuance to the stated
redemption date of the notes which is September 1, 2001.

The Company has also reclassified certain items on its statements of cash flows
to conform with the presentation required by Statement of Financial Accounting
Standard No. 95, Statement of Cash Flows.


NOTE 11 - SUBSEQUENT EVENT - UNAUDITED

On January 2, 2002 the Company announced that it had executed a letter of intent
to acquire First Responder Group, Inc. On April 19, 2002 the letter of intent
was recinded.



                                     -F-10-